Eli Lilly is entering the emerging psychedelic medicine sector through an agreement to acquire AtaiBeckley, a clinical-stage biotechnology company developing treatments for serious mental health conditions. The transaction is valued at approximately $2.8 billion upfront and could reach $3.8 billion if specified clinical development and regulatory milestones are achieved.
Under the agreement, Lilly will pay $6.75 in cash for each outstanding AtaiBeckley share. Shareholders could receive an additional $2.50 per share through contingent value rights linked to the progress of the company’s two leading drug candidates. The upfront purchase price represents an approximately 40% premium to AtaiBeckley’s 30-day volume-weighted average share price through July 15, 2026.
The acquisition reflects growing investment in next-generation mental health treatments as pharmaceutical and biotechnology companies look beyond conventional antidepressants. AtaiBeckley is developing rapid-acting neuroplastogens intended to support neural connectivity in areas of the brain associated with mood regulation.
Explore the Emerging Mental Health Devices and Platforms Market
AtaiBeckley’s most advanced candidate, BPL-003, is an intranasal formulation of mebufotenin benzoate, a synthetic form of the psychedelic compound 5-MeO-DMT. It is being developed for treatment-resistant depression, a condition affecting patients who continue to experience significant symptoms despite receiving multiple existing therapies.
BPL-003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has entered Phase 3 development activities. In a Phase 2b study, the candidate produced rapid reductions in depressive symptoms following an in-clinic treatment session lasting approximately two hours. The reported benefits continued for several months, although the findings remain investigational and must be confirmed through larger late-stage trials.
Download the Complete TOC of the Emerging Mental Health Devices and Platforms Market
The acquisition also gives Lilly access to VLS-01, a DMT-based buccal film currently advancing through Phase 2b development for treatment-resistant depression. AtaiBeckley’s pipeline further includes EMP-01, an R-MDMA candidate being evaluated for social anxiety disorder.
For Lilly, the transaction expands its neuroscience portfolio and provides access to a developing category of interventional psychiatric treatments. AtaiBeckley could benefit from Lilly’s global clinical development resources, regulatory capabilities, financial strength, and commercial infrastructure.
The transaction is expected to close in the third quarter of 2026, subject to AtaiBeckley shareholder approval, regulatory clearance, and customary closing conditions. Its long-term value will depend on whether the acquired candidates successfully complete clinical trials, receive regulatory approval, satisfy drug-scheduling requirements, and gain acceptance within healthcare delivery systems.
Request a Sample of the Emerging Mental Health Devices and Platforms Market Before Competitors Move
